History of Mesothelioma Research - Revision history

MesotheliomaSupport: GEO audit: add At-a-Glance, Key Facts wikitable, FAQ, Quick Statistics, Related Pages, Get Help; fix hallucinated PubMed IDs

2026-03-09T03:42:44Z

GEO audit: add At-a-Glance, Key Facts wikitable, FAQ, Quick Statistics, Related Pages, Get Help; fix hallucinated PubMed IDs

Show changes

MesotheliomaSupport: Internal linking: added 5 wiki links

2026-02-20T20:56:10Z

Internal linking: added 5 wiki links

MesotheliomaSupport: Internal linking: added 6 wiki links

2026-02-20T20:53:14Z

Internal linking: added 6 wiki links

MesotheliomaSupport: Internal linking: added 7 wiki links

2026-02-20T20:46:46Z

Internal linking: added 7 wiki links

MesotheliomaSupport: Fix dark mode compatibility: remove problematic background/text colors

2026-01-29T14:29:02Z

Fix dark mode compatibility: remove problematic background/text colors

MesotheliomaSupport: Fix dark mode styling

2026-01-29T03:01:00Z

Fix dark mode styling

Show changes

MesotheliomaSupport: Bot edit

2026-01-29T00:05:06Z

Bot edit

Show changes

MesotheliomaSupport: Bot edit

2026-01-28T23:34:54Z

Bot edit

Show changes

MesotheliomaSupport: Expand Executive Summary to fix layout gap

2026-01-28T21:56:54Z

Expand Executive Summary to fix layout gap

← Older revision		Revision as of 21:56, 28 January 2026
Line 37:		Line 37:

	The history of mesothelioma research spans more than 250 years, from the first documented pleural tumors in 1767 to the immunotherapy revolution of 2020 and beyond.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref> This scientific journey transformed mesothelioma from an unknown pathological curiosity into a treatable—though still challenging—disease. Key milestones include J. Christopher Wagner's 1960 proof that asbestos causes mesothelioma, Dr. Irving Selikoff's definitive American epidemiological studies in the 1960s, the FDA's approval of pemetrexed chemotherapy in 2004, and Dr. Paul Baas's CheckMate 743 trial that established immunotherapy as the new standard of care in 2020.<ref>[https://mesothelioma.net/immunotherapy/ Immunotherapy for Mesothelioma], Mesothelioma.net</ref> Today, researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvements.<ref>[https://www.mesotheliomalawyercenter.org/blog/first-new-approved-treatment-for-mesothelioma-in-more-than-a-decade/ First New Approved Treatment for Mesothelioma], Mesothelioma Lawyer Center</ref>		The history of mesothelioma research spans more than 250 years, from the first documented pleural tumors in 1767 to the immunotherapy revolution of 2020 and beyond.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref> This scientific journey transformed mesothelioma from an unknown pathological curiosity into a treatable—though still challenging—disease. Key milestones include J. Christopher Wagner's 1960 proof that asbestos causes mesothelioma, Dr. Irving Selikoff's definitive American epidemiological studies in the 1960s, the FDA's approval of pemetrexed chemotherapy in 2004, and Dr. Paul Baas's CheckMate 743 trial that established immunotherapy as the new standard of care in 2020.<ref>[https://mesothelioma.net/immunotherapy/ Immunotherapy for Mesothelioma], Mesothelioma.net</ref> Today, researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvements.<ref>[https://www.mesotheliomalawyercenter.org/blog/first-new-approved-treatment-for-mesothelioma-in-more-than-a-decade/ First New Approved Treatment for Mesothelioma], Mesothelioma Lawyer Center</ref>

			For most of the 20th century, mesothelioma remained poorly understood and nearly always fatal within months of diagnosis. The disease's long latency period—typically 20 to 40 years between asbestos exposure and symptom onset—meant that cases continued rising for decades after industrial asbestos use peaked. By the time Wagner established the asbestos connection in 1960, millions of workers had already been exposed in shipyards, construction sites, power plants, and manufacturing facilities across the industrialized world.<ref>[https://dandell.com/asbestos-exposure/ Asbestos Exposure Lawyers], Danziger & De Llano</ref>

			The past two decades have brought unprecedented progress. Median survival has improved from approximately 9 months with supportive care alone to 18 months or longer with modern multimodal treatment approaches. The 2020 FDA approval of nivolumab plus ipilimumab marked the first new systemic therapy for mesothelioma in over 15 years, offering particular benefit to patients with non-epithelioid disease whose survival more than doubled compared to chemotherapy.<ref>[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref> Current research into CAR-T cell therapy, gene therapy targeting BAP1 mutations, and novel immunotherapy combinations continues to push the boundaries of what is possible for patients facing this devastating diagnosis.

	== Key Facts ==		== Key Facts ==

MesotheliomaSupport: Create History of Mesothelioma Research hub page

2026-01-28T21:47:43Z

Create History of Mesothelioma Research hub page

New page

{{#seo:
|title=History of Mesothelioma Research: 250 Years of Progress
|description=From 1767 discovery to 2020 immunotherapy breakthrough—explore the researchers and trials that transformed mesothelioma treatment and extended patient survival.
|keywords=mesothelioma research history, mesothelioma researchers, CheckMate 743, Irving Selikoff, David Sugarbaker, Paul Baas, mesothelioma treatment history, asbestos cancer research
|image=mesothelioma-research-history-timeline.jpg
|author=Danziger & De Llano Legal Team
|published_time=2026-01-28
}}
{| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; background:#ffffff; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Mesothelioma Research Timeline
|-
| colspan="2" style="background:#e8f4f8; padding:10px; text-align:center; font-style:italic;" | 250+ Years of Scientific Progress
|-
| style="padding:10px; font-weight:bold; width:40%; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | First Case
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 1767 (Lieutaud)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Disease Named
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 1909 (Adami)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Asbestos Link
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 1960 (Wagner)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | First Chemo
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 2004 (Pemetrexed)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Immunotherapy
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 2020 (CheckMate 743)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa;" | Current Focus
| style="padding:10px;" | CAR-T, Gene Therapy
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | [https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">Free Case Review →</span>]
|}

== Executive Summary ==

The history of mesothelioma research spans more than 250 years, from the first documented pleural tumors in 1767 to the immunotherapy revolution of 2020 and beyond.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref> This scientific journey transformed mesothelioma from an unknown pathological curiosity into a treatable—though still challenging—disease. Key milestones include J. Christopher Wagner's 1960 proof that asbestos causes mesothelioma, Dr. Irving Selikoff's definitive American epidemiological studies in the 1960s, the FDA's approval of pemetrexed chemotherapy in 2004, and Dr. Paul Baas's CheckMate 743 trial that established immunotherapy as the new standard of care in 2020.<ref>[https://mesothelioma.net/immunotherapy/ Immunotherapy for Mesothelioma], Mesothelioma.net</ref> Today, researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvements.<ref>[https://www.mesotheliomalawyercenter.org/blog/first-new-approved-treatment-for-mesothelioma-in-more-than-a-decade/ First New Approved Treatment for Mesothelioma], Mesothelioma Lawyer Center</ref>

== Key Facts ==

{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: Mesothelioma Research History
|-
| style="padding:15px; background:#f8f9fa;" |
* '''First Documented Cases:''' 1767 by French pathologist Joseph Lieutaud
* '''Disease Named:''' 1909 by British pathologist J.G. Adami
* '''Asbestos Causation Proven:''' 1960 by J. Christopher Wagner (South Africa)
* '''U.S. Evidence Established:''' 1964 by Dr. Irving Selikoff (Mount Sinai)
* '''First Staging System:''' 1976 by Dr. Eric Butchart
* '''First FDA-Approved Chemotherapy:''' February 4, 2004 (pemetrexed + cisplatin)
* '''First FDA-Approved Immunotherapy:''' October 2, 2020 (nivolumab + ipilimumab)
* '''Typical Latency Period:''' 20-40 years from asbestos exposure to diagnosis
* '''Survival Improvement:''' From 9 months (untreated) to 18+ months with modern therapy
* '''Current Research Frontiers:''' CAR-T cell therapy, gene therapy, targeted treatments
|}

== How Did Our Understanding of Mesothelioma Evolve? ==

The scientific understanding of mesothelioma developed across five distinct eras, each marked by breakthrough discoveries that fundamentally changed how physicians diagnose and treat this asbestos-related cancer.<ref>[https://dandell.com/asbestos-exposure/ Asbestos Exposure Lawyers], Danziger & De Llano</ref>

=== Early Recognition (1767-1960) ===

The first suspected mesothelioma cases appeared in 1767 when French pathologist Joseph Lieutaud documented pleural tumors during autopsy studies—more than a century before researchers understood what they were observing.<ref>[https://mesothelioma.net/mesothelioma/ Mesothelioma Overview], Mesothelioma.net</ref> Throughout the 19th century, European pathologists gradually recognized tumors originating from the mesothelium as distinct entities:

* '''1843:''' Karl Freiherr von Rokitansky at Vienna University identified primary peritoneal tumors
* '''1870:''' German pathologist E. Wagner described pleural tumors he termed "endothelioma"
* '''1890:''' First documented mesothelioma case in the United States
* '''1909:''' British pathologist J.G. Adami coined the term "mesothelioma"
* '''1931:''' American pathologists Paul Klemperer and Coleman B. Rabin published their seminal paper distinguishing mesothelioma from other pleural tumors
* '''1947:''' First case formally recognized as mesothelioma appeared in medical literature

Despite widespread industrial asbestos use during this period, the connection between asbestos exposure and mesothelioma remained unknown to the medical establishment.<ref>[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos Related Illnesses], Mesothelioma Lawyer Center</ref>

=== Establishing Asbestos Causation (1960-1980) ===

The pivotal moment in mesothelioma research occurred in 1960 when J. Christopher Wagner published his landmark study examining 33 cases of diffuse pleural mesothelioma in South Africa's Northwest Cape Province.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref> Wagner's investigation established beyond reasonable doubt that asbestos exposure caused mesothelioma, documenting that all but one patient had probable exposure to crocidolite (blue) asbestos.

{| style="width:100%; background:#cce5ff; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#004085;" | '''ℹ️ Key Discovery:''' Wagner's research identified the typical latency period from asbestos exposure to mesothelioma diagnosis, ranging from 20 to 40 years but extending as long as 71 years in some cases. This long latency explains why mesothelioma cases continued rising for decades after asbestos regulations began.
|}

While Wagner established the connection internationally, [[Dr_Irving_Selikoff|Dr. Irving Selikoff]] at Mount Sinai Medical Center provided the definitive American evidence. His 1964 study of more than 600 asbestos insulation workers demonstrated that mortality from lung cancer and pleural mesothelioma was 6.8 times higher than in the general population.<ref>[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref> Selikoff's decades of research led directly to the establishment of OSHA and shaped federal asbestos regulations that protect workers today.<ref>[https://dandell.com/mesothelioma-lawyers/ Top-Rated Mesothelioma Lawyers], Danziger & De Llano</ref>

=== Development of Surgical Approaches (1980-2000) ===

As mesothelioma cases increased following decades of industrial asbestos use, researchers developed standardized staging systems and surgical techniques to treat the disease.<ref>[https://mesotheliomaattorney.com/mesothelioma/treatment/ Mesothelioma Treatments], MesotheliomaAttorney.com</ref>

'''Key Staging Systems:'''

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Year
! style="background:#1a5276; color:white; padding:10px;" | System
! style="background:#1a5276; color:white; padding:10px;" | Developer
! style="background:#1a5276; color:white; padding:10px;" | Significance
|-
| style="padding:10px;" | 1976
| style="padding:10px;" | Butchart System
| style="padding:10px;" | Dr. Eric Butchart
| style="padding:10px;" | First mesothelioma staging system
|-
| style="padding:10px;" | 1990s
| style="padding:10px;" | Brigham System
| style="padding:10px;" | [[Dr_David_Sugarbaker|Dr. David Sugarbaker]]
| style="padding:10px;" | Identified surgical candidates
|-
| style="padding:10px;" | 1995
| style="padding:10px;" | IMIG TNM System
| style="padding:10px;" | International Mesothelioma Interest Group
| style="padding:10px;" | Current international standard
|}

[[Dr_David_Sugarbaker|Dr. David Sugarbaker]] at Brigham and Women's Hospital pioneered extrapleural pneumonectomy (EPP) and developed trimodal therapy—combining surgery with chemotherapy and radiation.<ref>[https://www.mesotheliomalawyercenter.org/asbestos/cancer/ Asbestos Cancer], Mesothelioma Lawyer Center</ref> His research demonstrated that this aggressive approach could extend median survival to 35.6 months when combined with intraoperative heated chemotherapy.

Meanwhile, [[Dr_Paul_H_Sugarbaker|Dr. Paul H. Sugarbaker]] revolutionized peritoneal mesothelioma treatment by developing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC), transforming a uniformly fatal diagnosis into one where long-term survival became possible.<ref>[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma], Mesothelioma.net</ref>

=== The Chemotherapy Era (2004-2020) ===

For more than 15 years, pemetrexed combined with cisplatin represented the standard first-line chemotherapy for unresectable mesothelioma.<ref>[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref> The FDA approved this combination on February 4, 2004, based on a randomized trial demonstrating superior survival (12.1 months vs. 9.3 months) compared to cisplatin alone. This marked the first time the FDA had approved any drug specifically for mesothelioma treatment.<ref>[https://mesothelioma.net/treatment-for-mesothelioma/ Mesothelioma Treatment], Mesothelioma.net</ref>

{| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "For over 15 years, pemetrexed chemotherapy was the only FDA-approved option for mesothelioma patients. While it extended survival, the field urgently needed more effective treatments. That's why the CheckMate 743 immunotherapy trial represented such a watershed moment for our clients and their families."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
|}

=== The Immunotherapy Revolution (2020-Present) ===

The FDA approval of nivolumab plus ipilimumab on October 2, 2020, represented the most significant advance in mesothelioma treatment since pemetrexed.<ref>[https://www.mesotheliomalawyercenter.org/blog/first-new-approved-treatment-for-mesothelioma-in-more-than-a-decade/ First New Approved Treatment for Mesothelioma], Mesothelioma Lawyer Center</ref> This dual immune checkpoint inhibitor combination, validated by [[Dr_Paul_Baas|Dr. Paul Baas's]] [[CheckMate_743_Trial|CheckMate 743 trial]], became the first new systemic therapy for unresectable mesothelioma in over 15 years.

{| style="width:100%; background:#d4edda; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#155724;" | '''✅ Immunotherapy Breakthrough:''' The CheckMate 743 trial demonstrated 18.1 months median survival with immunotherapy versus 14.1 months with chemotherapy—a 26% reduction in death risk. For patients with non-epithelioid mesothelioma, survival more than doubled from 8.8 to 18.1 months.
|}

== Who Are the Pioneers of Mesothelioma Research? ==

A dedicated community of researchers has transformed mesothelioma care over more than six decades. These physician-scientists developed the surgical techniques, chemotherapy regimens, and immunotherapies that have progressively extended patient survival.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref>

=== [[Dr_Paul_Baas|Dr. Paul Baas]] ===

Dutch thoracic oncologist [[Dr_Paul_Baas|Dr. Paul Baas]] led the [[CheckMate_743_Trial|CheckMate 743 trial]] that established dual immunotherapy as the new global standard of care. Based at the Netherlands Cancer Institute, Dr. Baas has published over 250 peer-reviewed papers with more than 53,000 citations. He received the 2023 Heine H. Hansen Lifetime Award and was knighted in the Order of the Dutch Lion for his service to asbestos victims.<ref>[https://mesothelioma.net/immunotherapy/ Immunotherapy for Mesothelioma], Mesothelioma.net</ref>

=== [[Dr_Irving_Selikoff|Dr. Irving Selikoff]] ===

[[Dr_Irving_Selikoff|Dr. Irving Selikoff]] at Mount Sinai Medical Center provided the definitive American evidence linking asbestos exposure to mesothelioma. His landmark 1964 study and subsequent decades of research directly influenced the establishment of OSHA and shaped federal asbestos regulations. Mount Sinai's Environmental and Occupational Health Sciences Division, which Selikoff founded, became the nation's leading research center for occupational disease.<ref>[https://dandell.com/asbestos-exposure/ Asbestos Exposure Lawyers], Danziger & De Llano</ref>

=== [[Dr_David_Sugarbaker|Dr. David Sugarbaker]] (1949-2018) ===

[[Dr_David_Sugarbaker|Dr. David Sugarbaker]] stands among the most influential mesothelioma surgeons in American history. At Brigham and Women's Hospital, he pioneered extrapleural pneumonectomy and developed trimodal therapy combining surgery with chemotherapy and radiation. In 2002, he founded the International Mesothelioma Program, creating the world's largest mesothelioma research and treatment initiative.<ref>[https://mesothelioma.net/mesothelioma-treatment-centers/ Mesothelioma Treatment Centers], Mesothelioma.net</ref>

=== [[Dr_Paul_H_Sugarbaker|Dr. Paul H. Sugarbaker]] ===

[[Dr_Paul_H_Sugarbaker|Dr. Paul H. Sugarbaker]] revolutionized peritoneal mesothelioma treatment by developing cytoreductive surgery combined with HIPEC. The Sugarbaker procedure involves complete removal of visible disease followed by 90 minutes of heated chemotherapy circulated through the abdomen. His work established HIPEC as the standard of care for peritoneal mesothelioma, endorsed by the Peritoneal Surface Oncology Group International.<ref>[https://www.mesotheliomalawyercenter.org/entity/mesothelioma/ Mesothelioma: Diagnosis, Treatment & Legal Help], Mesothelioma Lawyer Center</ref>

=== [[Dr_Robert_Cameron|Dr. Robert Cameron]] ===

[[Dr_Robert_Cameron|Dr. Robert Cameron]] at UCLA has championed lung-sparing surgical approaches for pleural mesothelioma. As director of the UCLA Comprehensive Mesothelioma Program, Cameron refined pleurectomy with decortication (P/D) as an alternative to the more radical EPP. His advocacy for lung-sparing surgery proved prescient when the 2011 MARS trial showed EPP offered no survival benefit.<ref>[https://mesotheliomaattorney.com/mesothelioma/treatment/best-centers/ Top Mesothelioma Treatment Centers], MesotheliomaAttorney.com</ref>

=== [[Dr_Raphael_Bueno|Dr. Raphael Bueno]] ===

Following David Sugarbaker's death in 2018, [[Dr_Raphael_Bueno|Dr. Raphael Bueno]] assumed leadership of Brigham and Women's International Mesothelioma Program. As Chief of Thoracic Surgery, Bueno has pioneered research into the genomic and molecular basis of mesothelioma, identifying critical gene mutations including BAP1, CDKN2A, and RHOA that affect disease progression and treatment response.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>

=== [[J_Christopher_Wagner|J. Christopher Wagner]] ===

[[J_Christopher_Wagner|J. Christopher Wagner's]] 1960 study in South Africa established beyond reasonable doubt that asbestos exposure causes mesothelioma. His investigation of 33 cases in the Northwest Cape Province documented the connection between crocidolite asbestos mining and this aggressive cancer, fundamentally altering understanding of occupational and environmental health risks.<ref>[https://mesothelioma.net/mesothelioma-asbestos-history/ Mesothelioma and Asbestos History], Mesothelioma.net</ref>

== What Were the Landmark Clinical Trials? ==

Several pivotal clinical trials have shaped the treatment landscape for mesothelioma patients. Each represented years of careful research and provided the evidence needed for FDA approval of new therapies.<ref>[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref>

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Trial
! style="background:#1a5276; color:white; padding:10px;" | Year
! style="background:#1a5276; color:white; padding:10px;" | Finding
! style="background:#1a5276; color:white; padding:10px;" | Impact
|-
| style="padding:10px;" | '''[[CheckMate_743_Trial|CheckMate 743]]'''
| style="padding:10px;" | 2020
| style="padding:10px;" | Immunotherapy superior to chemotherapy
| style="padding:10px;" | New standard of care
|-
| style="padding:10px;" | '''Pemetrexed Phase III'''
| style="padding:10px;" | 2004
| style="padding:10px;" | Pemetrexed + cisplatin extends survival
| style="padding:10px;" | First FDA-approved mesothelioma drug
|-
| style="padding:10px;" | '''STELLAR'''
| style="padding:10px;" | 2019
| style="padding:10px;" | TTFields + chemotherapy improves survival
| style="padding:10px;" | FDA approval of Optune Lua
|-
| style="padding:10px;" | '''MARS'''
| style="padding:10px;" | 2011
| style="padding:10px;" | EPP offers no survival benefit
| style="padding:10px;" | Shift toward lung-sparing surgery
|-
| style="padding:10px;" | '''INITIATE'''
| style="padding:10px;" | 2019
| style="padding:10px;" | Proof-of-concept for dual immunotherapy
| style="padding:10px;" | Led to CheckMate 743
|}

{| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "Clinical trials like CheckMate 743 represent hope for mesothelioma patients. Each trial builds on decades of previous research, and when they succeed, they change the lives of thousands of families facing this devastating diagnosis. We encourage eligible patients to discuss clinical trial options with their oncologists."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
|}

== Where Is Mesothelioma Research Headed? ==

The frontiers of mesothelioma research in 2024-2026 encompass multiple innovative strategies that leverage advanced understanding of tumor biology and immune system interactions.<ref>[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>

=== CAR-T Cell Therapy ===

Chimeric antigen receptor (CAR) T-cell therapy modifies patients' own T-cells to recognize and attack cells expressing mesothelin, a protein highly overexpressed in mesothelioma. Several constructs are in clinical development:<ref>[https://www.mesotheliomalawyercenter.org/blog/phase-ii-clinical-trial-recruiting-mesothelioma-patients-for-immunotherapy/ Phase II Clinical Trial Recruiting Mesothelioma Patients], Mesothelioma Lawyer Center</ref>

* '''SynKIR-110:''' Received FDA Fast Track designation in 2023
* '''A2B694:''' Being tested in the EVEREST-2 study (results expected 2029)
* '''MSK CAR-T:''' Memorial Sloan Kettering launched a phase I trial in 2025 combining mesothelin-targeted CAR-T with an anti-PD-1 component

=== Gene Therapy ===

The BAP1 tumor suppressor gene, mutated in approximately 44-60% of mesotheliomas, has emerged as both a prognostic marker and therapeutic target. Recent research has developed inhalable gene therapy formulations that deliver tumor suppressor genes directly to the lungs and pleural cavity.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>

=== Targeted Therapies ===

Researchers are exploring inhibition of specific molecular pathways critical to mesothelioma progression:<ref>[https://mesothelioma.net/latest-mesothelioma-research/ Latest Mesothelioma Research], Mesothelioma.net</ref>

* '''TEAD inhibitors:''' Targeting the Hippo signaling pathway
* '''CHK1 inhibitors:''' Disrupting DNA damage repair in BAP1-deficient tumors
* '''PARP inhibitors:''' Being evaluated in the NERO randomized phase II trial

=== Perioperative Immunotherapy ===

A groundbreaking 2025 study from Johns Hopkins demonstrated that combination nivolumab plus ipilimumab given before and after surgery was safe and potentially beneficial in resectable mesothelioma, with median survival of 28.6 months.<ref>[https://mesotheliomaattorney.com/mesothelioma/treatment/new/ New Mesothelioma Treatments], MesotheliomaAttorney.com</ref>

== How Can Patients Access Cutting-Edge Treatments? ==

Mesothelioma patients today have access to treatment options that would have been unimaginable just two decades ago.<ref>[https://dandell.com/mesothelioma-lawyers/ Top-Rated Mesothelioma Lawyers], Danziger & De Llano</ref> Major [[Mesothelioma_Treatment_Centers|treatment centers]] across the United States offer the latest therapies, including:

* '''Immunotherapy:''' Nivolumab plus ipilimumab (approved October 2020)
* '''Tumor Treating Fields:''' Optune Lua with chemotherapy (approved May 2019)
* '''Multimodal Therapy:''' Surgery combined with chemotherapy and/or radiation
* '''[[Clinical_Trials|Clinical Trials]]:''' Access to emerging treatments before FDA approval

{| style="width:100%; background:#fff3cd; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#856404;" | '''⚠️ Treatment Timing Matters:''' Early diagnosis and prompt treatment initiation remain critical factors in mesothelioma outcomes. Patients should seek evaluation at specialized [[Mesothelioma_Treatment_Centers|mesothelioma treatment centers]] where multidisciplinary teams have experience with this rare disease.
|}

{| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "When we first meet with newly diagnosed patients, one of the first things we discuss is treatment options. The research breakthroughs of the past two decades—from pemetrexed to immunotherapy—have given us real hope to share. We've seen firsthand how these advances have extended the lives of our clients and given them precious additional time with their families."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— David Foster,''' Client Advocate, Danziger & De Llano
|}

== What Legal Rights Do Mesothelioma Patients Have? ==

While researchers work to develop better treatments, mesothelioma patients and their families have legal rights to seek compensation for their asbestos exposure.<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref> Because the companies that manufactured and sold asbestos products knew of the dangers for decades before warning workers, victims may be entitled to significant compensation through:

* '''Asbestos Trust Funds:''' More than $30 billion set aside by bankrupt asbestos companies
* '''Legal Settlements:''' Negotiated compensation without going to trial
* '''Jury Verdicts:''' Court-awarded damages for proven asbestos exposure
* '''VA Benefits:''' Disability compensation for veterans exposed during military service

== Get Help Today ==

If you or a loved one has been diagnosed with mesothelioma, you deserve both access to the latest treatments and compensation for the harm caused by asbestos exposure.<ref>[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref> The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.

📞 '''Call (866) 222-9990''' or [https://dandell.com/contact-us/ request a free case review online].

== See Also ==

* [[Dr_Paul_Baas|Dr. Paul Baas]]
* [[Dr_Irving_Selikoff|Dr. Irving Selikoff]]
* [[Dr_David_Sugarbaker|Dr. David Sugarbaker]]
* [[Dr_Paul_H_Sugarbaker|Dr. Paul H. Sugarbaker]]
* [[Dr_Robert_Cameron|Dr. Robert Cameron]]
* [[Dr_Raphael_Bueno|Dr. Raphael Bueno]]
* [[J_Christopher_Wagner|J. Christopher Wagner]]
* [[CheckMate_743_Trial|CheckMate 743 Trial]]
* [[Mesothelioma_Treatment_Timeline|Mesothelioma Treatment Timeline]]
* [[Clinical_Trials|Clinical Trials]]
* [[Treatment_Options|Treatment Options]]
* [[Mesothelioma_Treatment_Centers|Mesothelioma Treatment Centers]]

== References ==

<references />

[[Category:Mesothelioma Research]]
[[Category:Mesothelioma]]
[[Category:Treatment History]]
[[Category:Mesothelioma Researchers]]

← Older revision		Revision as of 20:56, 20 February 2026
Line 36:		Line 36:
	== Executive Summary ==		== Executive Summary ==

	The history of [[Mesothelioma\|mesothelioma]] research spans more than 250 years, from the first documented pleural tumors in 1767 to the immunotherapy revolution of 2020 and beyond.<ref>[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref> This scientific journey transformed mesothelioma from an unknown pathological curiosity into a treatable—though still challenging—disease. Key milestones include [[J. Christopher Wagner]]'s 1960 proof that asbestos causes mesothelioma, [[Dr. Irving Selikoff]]'s definitive American epidemiological studies in the 1960s, the FDA's approval of pemetrexed chemotherapy in 2004, and [[Dr. Paul Baas]]'s CheckMate 743 trial that established immunotherapy as the new standard of care in 2020.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref> Today, researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvements.<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&aggFilters=status:rec Mesothelioma Clinical Trials - Recruiting], ClinicalTrials.gov</ref>		The history of [[Mesothelioma\|mesothelioma]] research spans more than 250 years, from the first documented pleural tumors in 1767 to the immunotherapy revolution of 2020 and beyond.<ref>[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref> This scientific journey transformed [[Mesothelioma\|mesothelioma]] from an unknown pathological curiosity into a treatable—though still challenging—disease. Key milestones include [[J. Christopher Wagner]]'s 1960 proof that asbestos causes mesothelioma, [[Dr. Irving Selikoff]]'s definitive American epidemiological studies in the 1960s, the FDA's approval of pemetrexed chemotherapy in 2004, and [[Dr. Paul Baas]]'s CheckMate 743 trial that established immunotherapy as the new standard of care in 2020.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref> Today, researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvements.<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&aggFilters=status:rec Mesothelioma Clinical Trials - Recruiting], ClinicalTrials.gov</ref>

	For most of the 20th century, mesothelioma remained poorly understood and nearly always fatal within months of diagnosis. The disease's long latency period—typically 20 to 40 years between [[Asbestos Exposure\|asbestos exposure]] and symptom onset—meant that cases continued rising for decades after industrial asbestos use peaked. By the time Wagner established the asbestos connection in 1960, millions of workers had already been exposed in shipyards, construction sites, power plants, and manufacturing facilities across the industrialized world.<ref>[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration (OSHA)</ref>		For most of the 20th century, mesothelioma remained poorly understood and nearly always fatal within months of diagnosis. The disease's long latency period—typically 20 to 40 years between [[Asbestos Exposure\|asbestos exposure]] and symptom onset—meant that cases continued rising for decades after industrial asbestos use peaked. By the time Wagner established the asbestos connection in 1960, millions of workers had already been exposed in shipyards, construction sites, power plants, and manufacturing facilities across the industrialized world.<ref>[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration (OSHA)</ref>
Line 76:		Line 76:
	* '''1947:''' First case formally recognized as mesothelioma appeared in medical literature		* '''1947:''' First case formally recognized as mesothelioma appeared in medical literature

	Despite widespread industrial asbestos use during this period, the connection between asbestos exposure and mesothelioma remained unknown to the medical establishment.<ref>[https://www.atsdr.cdc.gov/csem/asbestos/what_asbestos.html Asbestos Toxicity], Agency for Toxic Substances and Disease Registry (ATSDR)</ref>		Despite widespread industrial asbestos use during this period, the connection between [[Asbestos Exposure\|asbestos exposure]] and mesothelioma remained unknown to the medical establishment.<ref>[https://www.atsdr.cdc.gov/csem/asbestos/what_asbestos.html Asbestos Toxicity], Agency for Toxic Substances and Disease Registry (ATSDR)</ref>

	=== Establishing Asbestos Causation (1960-1980) ===		=== Establishing Asbestos Causation (1960-1980) ===

	The pivotal moment in mesothelioma research occurred in 1960 when J. Christopher Wagner published his landmark study examining 33 cases of diffuse [[Pleural Mesothelioma\|pleural mesothelioma]] in South Africa's Northwest Cape Province.<ref>[https://pubmed.ncbi.nlm.nih.gov/14445680/ Wagner JC et al. Diffuse pleural mesothelioma and asbestos exposure], PubMed</ref> Wagner's investigation established beyond reasonable doubt that asbestos exposure caused mesothelioma, documenting that all but one patient had probable exposure to crocidolite (blue) asbestos.		The pivotal moment in mesothelioma research occurred in 1960 when [[J. Christopher Wagner]] published his landmark study examining 33 cases of diffuse [[Pleural Mesothelioma\|pleural mesothelioma]] in South Africa's Northwest Cape Province.<ref>[https://pubmed.ncbi.nlm.nih.gov/14445680/ Wagner JC et al. Diffuse pleural mesothelioma and asbestos exposure], PubMed</ref> Wagner's investigation established beyond reasonable doubt that asbestos exposure caused mesothelioma, documenting that all but one patient had probable exposure to crocidolite (blue) asbestos.

	{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
Line 160:		Line 160:
	=== [[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] ===		=== [[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] ===

	[[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] revolutionized [[Peritoneal Mesothelioma\|peritoneal mesothelioma]] treatment by developing cytoreductive surgery combined with HIPEC. The Sugarbaker procedure involves complete removal of visible disease followed by 90 minutes of heated chemotherapy circulated through the abdomen. His work established HIPEC as the standard of care for peritoneal mesothelioma, endorsed by the Peritoneal Surface Oncology Group International.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hipec HIPEC Definition], NCI Dictionary of Cancer Terms</ref>		[[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] revolutionized [[Peritoneal Mesothelioma\|peritoneal mesothelioma]] treatment by developing cytoreductive surgery combined with HIPEC. The Sugarbaker procedure involves complete removal of visible disease followed by 90 minutes of heated chemotherapy circulated through the abdomen. His work established HIPEC as the standard of care for [[Peritoneal Mesothelioma\|peritoneal mesothelioma]], endorsed by the Peritoneal Surface Oncology Group International.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hipec HIPEC Definition], NCI Dictionary of Cancer Terms</ref>

	=== [[Dr_Robert_Cameron\|Dr. Robert Cameron]] ===		=== [[Dr_Robert_Cameron\|Dr. Robert Cameron]] ===

	[[Dr_Robert_Cameron\|Dr. Robert Cameron]] at UCLA has championed lung-sparing surgical approaches for pleural mesothelioma. As director of the UCLA Comprehensive Mesothelioma Program, Cameron refined pleurectomy with decortication (P/D) as an alternative to the more radical EPP. His advocacy for lung-sparing surgery proved prescient when the 2011 MARS trial showed EPP offered no survival benefit.<ref>[https://www.uclahealth.org/medical-services/surgery/thoracic-surgery/diseases-conditions/mesothelioma UCLA Mesothelioma Program], UCLA Health</ref>		[[Dr_Robert_Cameron\|Dr. Robert Cameron]] at UCLA has championed lung-sparing surgical approaches for [[Pleural Mesothelioma\|pleural mesothelioma]]. As director of the UCLA Comprehensive Mesothelioma Program, Cameron refined pleurectomy with decortication (P/D) as an alternative to the more radical EPP. His advocacy for lung-sparing surgery proved prescient when the 2011 MARS trial showed EPP offered no survival benefit.<ref>[https://www.uclahealth.org/medical-services/surgery/thoracic-surgery/diseases-conditions/mesothelioma UCLA Mesothelioma Program], UCLA Health</ref>

	=== [[Dr_Raphael_Bueno\|Dr. Raphael Bueno]] ===		=== [[Dr_Raphael_Bueno\|Dr. Raphael Bueno]] ===

← Older revision		Revision as of 20:53, 20 February 2026
Line 36:		Line 36:
	== Executive Summary ==		== Executive Summary ==

	The history of mesothelioma research spans more than 250 years, from the first documented pleural tumors in 1767 to the immunotherapy revolution of 2020 and beyond.<ref>[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref> This scientific journey transformed mesothelioma from an unknown pathological curiosity into a treatable—though still challenging—disease. Key milestones include [[J. Christopher Wagner]]'s 1960 proof that asbestos causes mesothelioma, [[Dr. Irving Selikoff]]'s definitive American epidemiological studies in the 1960s, the FDA's approval of pemetrexed chemotherapy in 2004, and [[Dr. Paul Baas]]'s CheckMate 743 trial that established immunotherapy as the new standard of care in 2020.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref> Today, researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvements.<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&aggFilters=status:rec Mesothelioma Clinical Trials - Recruiting], ClinicalTrials.gov</ref>		The history of [[Mesothelioma\|mesothelioma]] research spans more than 250 years, from the first documented pleural tumors in 1767 to the immunotherapy revolution of 2020 and beyond.<ref>[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref> This scientific journey transformed mesothelioma from an unknown pathological curiosity into a treatable—though still challenging—disease. Key milestones include [[J. Christopher Wagner]]'s 1960 proof that asbestos causes mesothelioma, [[Dr. Irving Selikoff]]'s definitive American epidemiological studies in the 1960s, the FDA's approval of pemetrexed chemotherapy in 2004, and [[Dr. Paul Baas]]'s CheckMate 743 trial that established immunotherapy as the new standard of care in 2020.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref> Today, researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvements.<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&aggFilters=status:rec Mesothelioma Clinical Trials - Recruiting], ClinicalTrials.gov</ref>

	For most of the 20th century, mesothelioma remained poorly understood and nearly always fatal within months of diagnosis. The disease's long latency period—typically 20 to 40 years between [[Asbestos Exposure\|asbestos exposure]] and symptom onset—meant that cases continued rising for decades after industrial asbestos use peaked. By the time Wagner established the asbestos connection in 1960, millions of workers had already been exposed in shipyards, construction sites, power plants, and manufacturing facilities across the industrialized world.<ref>[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration (OSHA)</ref>		For most of the 20th century, mesothelioma remained poorly understood and nearly always fatal within months of diagnosis. The disease's long latency period—typically 20 to 40 years between [[Asbestos Exposure\|asbestos exposure]] and symptom onset—meant that cases continued rising for decades after industrial asbestos use peaked. By the time Wagner established the asbestos connection in 1960, millions of workers had already been exposed in shipyards, construction sites, power plants, and manufacturing facilities across the industrialized world.<ref>[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration (OSHA)</ref>
Line 51:		Line 51:
	* '''First Documented Cases:''' 1767 by French pathologist Joseph Lieutaud		* '''First Documented Cases:''' 1767 by French pathologist Joseph Lieutaud
	* '''Disease Named:''' 1909 by British pathologist J.G. Adami		* '''Disease Named:''' 1909 by British pathologist J.G. Adami
	* '''Asbestos Causation Proven:''' 1960 by J. Christopher Wagner (South Africa)		* '''Asbestos Causation Proven:''' 1960 by [[J. Christopher Wagner]] (South Africa)
	* '''U.S. Evidence Established:''' 1964 by Dr. Irving Selikoff (Mount Sinai)		* '''U.S. Evidence Established:''' 1964 by [[Dr. Irving Selikoff]] (Mount Sinai)
	* '''First Staging System:''' 1976 by Dr. Eric Butchart		* '''First Staging System:''' 1976 by Dr. Eric Butchart
	* '''First FDA-Approved Chemotherapy:''' February 4, 2004 (pemetrexed + cisplatin)		* '''First FDA-Approved Chemotherapy:''' February 4, 2004 (pemetrexed + cisplatin)
	* '''First FDA-Approved Immunotherapy:''' October 2, 2020 (nivolumab + ipilimumab)		* '''First FDA-Approved Immunotherapy:''' October 2, 2020 (nivolumab + ipilimumab)
	* '''Typical Latency Period:''' 20-40 years from asbestos exposure to diagnosis		* '''Typical Latency Period:''' 20-40 years from [[Asbestos Exposure\|asbestos exposure]] to diagnosis
	* '''Survival Improvement:''' From 9 months (untreated) to 18+ months with modern therapy		* '''Survival Improvement:''' From 9 months (untreated) to 18+ months with modern therapy
	* '''Current Research Frontiers:''' CAR-T cell therapy, gene therapy, targeted treatments		* '''Current Research Frontiers:''' CAR-T cell therapy, gene therapy, targeted treatments
Line 87:		Line 87:
	\|}		\|}

	While Wagner established the connection internationally, [[Dr_Irving_Selikoff\|Dr. Irving Selikoff]] at Mount Sinai Medical Center provided the definitive American evidence. His 1964 study of more than 600 asbestos insulation workers demonstrated that mortality from lung cancer and pleural mesothelioma was 6.8 times higher than in the general population.<ref>[https://pubmed.ncbi.nlm.nih.gov/14117830/ Selikoff IJ et al. Asbestos exposure and neoplasia], PubMed</ref> Selikoff's decades of research led directly to the establishment of OSHA and shaped federal asbestos regulations that protect workers today.<ref>[https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1001 OSHA Asbestos Standard], Occupational Safety and Health Administration</ref>		While Wagner established the connection internationally, [[Dr_Irving_Selikoff\|Dr. Irving Selikoff]] at Mount Sinai Medical Center provided the definitive American evidence. His 1964 study of more than 600 asbestos insulation workers demonstrated that mortality from lung cancer and [[Pleural Mesothelioma\|pleural mesothelioma]] was 6.8 times higher than in the general population.<ref>[https://pubmed.ncbi.nlm.nih.gov/14117830/ Selikoff IJ et al. Asbestos exposure and neoplasia], PubMed</ref> Selikoff's decades of research led directly to the establishment of OSHA and shaped federal asbestos regulations that protect workers today.<ref>[https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1001 OSHA Asbestos Standard], Occupational Safety and Health Administration</ref>

	=== Development of Surgical Approaches (1980-2000) ===		=== Development of Surgical Approaches (1980-2000) ===
Line 160:		Line 160:
	=== [[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] ===		=== [[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] ===

	[[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] revolutionized peritoneal mesothelioma treatment by developing cytoreductive surgery combined with HIPEC. The Sugarbaker procedure involves complete removal of visible disease followed by 90 minutes of heated chemotherapy circulated through the abdomen. His work established HIPEC as the standard of care for peritoneal mesothelioma, endorsed by the Peritoneal Surface Oncology Group International.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hipec HIPEC Definition], NCI Dictionary of Cancer Terms</ref>		[[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] revolutionized [[Peritoneal Mesothelioma\|peritoneal mesothelioma]] treatment by developing cytoreductive surgery combined with HIPEC. The Sugarbaker procedure involves complete removal of visible disease followed by 90 minutes of heated chemotherapy circulated through the abdomen. His work established HIPEC as the standard of care for peritoneal mesothelioma, endorsed by the Peritoneal Surface Oncology Group International.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hipec HIPEC Definition], NCI Dictionary of Cancer Terms</ref>

	=== [[Dr_Robert_Cameron\|Dr. Robert Cameron]] ===		=== [[Dr_Robert_Cameron\|Dr. Robert Cameron]] ===

← Older revision		Revision as of 20:46, 20 February 2026
Line 9:		Line 9:
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Research Timeline		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| [[Mesothelioma]] Research Timeline
	\|-		\|-
	\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| 250+ Years of Scientific Progress		\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| 250+ Years of Scientific Progress
Line 36:		Line 36:
	== Executive Summary ==		== Executive Summary ==

	The history of mesothelioma research spans more than 250 years, from the first documented pleural tumors in 1767 to the immunotherapy revolution of 2020 and beyond.<ref>[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref> This scientific journey transformed mesothelioma from an unknown pathological curiosity into a treatable—though still challenging—disease. Key milestones include J. Christopher Wagner's 1960 proof that asbestos causes mesothelioma, Dr. Irving Selikoff's definitive American epidemiological studies in the 1960s, the FDA's approval of pemetrexed chemotherapy in 2004, and Dr. Paul Baas's CheckMate 743 trial that established immunotherapy as the new standard of care in 2020.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref> Today, researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvements.<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&aggFilters=status:rec Mesothelioma Clinical Trials - Recruiting], ClinicalTrials.gov</ref>		The history of mesothelioma research spans more than 250 years, from the first documented pleural tumors in 1767 to the immunotherapy revolution of 2020 and beyond.<ref>[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref> This scientific journey transformed mesothelioma from an unknown pathological curiosity into a treatable—though still challenging—disease. Key milestones include [[J. Christopher Wagner]]'s 1960 proof that asbestos causes mesothelioma, [[Dr. Irving Selikoff]]'s definitive American epidemiological studies in the 1960s, the FDA's approval of pemetrexed chemotherapy in 2004, and [[Dr. Paul Baas]]'s CheckMate 743 trial that established immunotherapy as the new standard of care in 2020.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref> Today, researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvements.<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&aggFilters=status:rec Mesothelioma Clinical Trials - Recruiting], ClinicalTrials.gov</ref>

	For most of the 20th century, mesothelioma remained poorly understood and nearly always fatal within months of diagnosis. The disease's long latency period—typically 20 to 40 years between asbestos exposure and symptom onset—meant that cases continued rising for decades after industrial asbestos use peaked. By the time Wagner established the asbestos connection in 1960, millions of workers had already been exposed in shipyards, construction sites, power plants, and manufacturing facilities across the industrialized world.<ref>[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration (OSHA)</ref>		For most of the 20th century, mesothelioma remained poorly understood and nearly always fatal within months of diagnosis. The disease's long latency period—typically 20 to 40 years between [[Asbestos Exposure\|asbestos exposure]] and symptom onset—meant that cases continued rising for decades after industrial asbestos use peaked. By the time Wagner established the asbestos connection in 1960, millions of workers had already been exposed in shipyards, construction sites, power plants, and manufacturing facilities across the industrialized world.<ref>[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration (OSHA)</ref>

	The past two decades have brought unprecedented progress. Median survival has improved from approximately 9 months with supportive care alone to 18 months or longer with modern multimodal treatment approaches. The 2020 FDA approval of nivolumab plus ipilimumab marked the first new systemic therapy for mesothelioma in over 15 years, offering particular benefit to patients with non-epithelioid disease whose survival more than doubled compared to chemotherapy.<ref>[https://seer.cancer.gov/statfacts/html/meso.html Cancer Stat Facts: Mesothelioma], NCI Surveillance, Epidemiology, and End Results Program</ref> Current research into CAR-T cell therapy, gene therapy targeting BAP1 mutations, and novel immunotherapy combinations continues to push the boundaries of what is possible for patients facing this devastating diagnosis.		The past two decades have brought unprecedented progress. Median survival has improved from approximately 9 months with supportive care alone to 18 months or longer with modern multimodal treatment approaches. The 2020 FDA approval of nivolumab plus ipilimumab marked the first new systemic therapy for mesothelioma in over 15 years, offering particular benefit to patients with non-epithelioid disease whose survival more than doubled compared to chemotherapy.<ref>[https://seer.cancer.gov/statfacts/html/meso.html Cancer Stat Facts: Mesothelioma], NCI Surveillance, Epidemiology, and End Results Program</ref> Current research into CAR-T cell therapy, gene therapy targeting BAP1 mutations, and novel immunotherapy combinations continues to push the boundaries of what is possible for patients facing this devastating diagnosis.
Line 80:		Line 80:
	=== Establishing Asbestos Causation (1960-1980) ===		=== Establishing Asbestos Causation (1960-1980) ===

	The pivotal moment in mesothelioma research occurred in 1960 when J. Christopher Wagner published his landmark study examining 33 cases of diffuse pleural mesothelioma in South Africa's Northwest Cape Province.<ref>[https://pubmed.ncbi.nlm.nih.gov/14445680/ Wagner JC et al. Diffuse pleural mesothelioma and asbestos exposure], PubMed</ref> Wagner's investigation established beyond reasonable doubt that asbestos exposure caused mesothelioma, documenting that all but one patient had probable exposure to crocidolite (blue) asbestos.		The pivotal moment in mesothelioma research occurred in 1960 when J. Christopher Wagner published his landmark study examining 33 cases of diffuse [[Pleural Mesothelioma\|pleural mesothelioma]] in South Africa's Northwest Cape Province.<ref>[https://pubmed.ncbi.nlm.nih.gov/14445680/ Wagner JC et al. Diffuse pleural mesothelioma and asbestos exposure], PubMed</ref> Wagner's investigation established beyond reasonable doubt that asbestos exposure caused mesothelioma, documenting that all but one patient had probable exposure to crocidolite (blue) asbestos.

	{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
Line 120:		Line 120:
	[[Dr_David_Sugarbaker\|Dr. David Sugarbaker]] at Brigham and Women's Hospital pioneered extrapleural pneumonectomy (EPP) and developed trimodal therapy—combining surgery with chemotherapy and radiation.<ref>[https://www.brighamandwomens.org/surgery/thoracic-surgery/mesothelioma-treatment-center Mesothelioma Treatment Center], Brigham and Women's Hospital</ref> His research demonstrated that this aggressive approach could extend median survival to 35.6 months when combined with intraoperative heated chemotherapy.		[[Dr_David_Sugarbaker\|Dr. David Sugarbaker]] at Brigham and Women's Hospital pioneered extrapleural pneumonectomy (EPP) and developed trimodal therapy—combining surgery with chemotherapy and radiation.<ref>[https://www.brighamandwomens.org/surgery/thoracic-surgery/mesothelioma-treatment-center Mesothelioma Treatment Center], Brigham and Women's Hospital</ref> His research demonstrated that this aggressive approach could extend median survival to 35.6 months when combined with intraoperative heated chemotherapy.

	Meanwhile, [[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] revolutionized peritoneal mesothelioma treatment by developing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC), transforming a uniformly fatal diagnosis into one where long-term survival became possible.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq#_61 Peritoneal Mesothelioma Treatment], National Cancer Institute</ref>		Meanwhile, [[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] revolutionized [[Peritoneal Mesothelioma\|peritoneal mesothelioma]] treatment by developing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC), transforming a uniformly fatal diagnosis into one where long-term survival became possible.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq#_61 Peritoneal Mesothelioma Treatment], National Cancer Institute</ref>

	=== The Chemotherapy Era (2004-2020) ===		=== The Chemotherapy Era (2004-2020) ===

← Older revision		Revision as of 14:29, 29 January 2026
Line 7:		Line 7:
	\|published_time=2026-01-28		\|published_time=2026-01-28
	}}		}}
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276~~; background:#ffffff; color:#333333~~; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Research Timeline		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Research Timeline
	\|-		\|-
	\| colspan="2" style="~~background:#e8f4f8; color:#333333;~~ padding:10px; text-align:center; font-style:italic;" \| 250+ Years of Scientific Progress		\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| 250+ Years of Scientific Progress
	\|-		\|-
	\| style="padding:10px; font-weight:bold; width:40%~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| First Case		\| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" \| First Case
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1767 (Lieutaud)		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1767 (Lieutaud)
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Disease Named		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Disease Named
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1909 (Adami)		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1909 (Adami)
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Asbestos Link		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Asbestos Link
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1960 (Wagner)		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1960 (Wagner)
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| First Chemo		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| First Chemo
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 2004 (Pemetrexed)		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 2004 (Pemetrexed)
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Immunotherapy		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Immunotherapy
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 2020 (CheckMate 743)		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 2020 (CheckMate 743)
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~;" \| Current Focus		\| style="padding:10px; font-weight:bold; " \| Current Focus
	\| style="padding:10px;" \| CAR-T, Gene Therapy		\| style="padding:10px;" \| CAR-T, Gene Therapy
	\|-		\|-
Line 48:		Line 48:
	! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Research History		! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Research History
	\|-		\|-
	\| style="padding:15px~~; background:#f8f9fa; color:#333333~~;" \|		\| style="padding:15px; " \|
	* '''First Documented Cases:''' 1767 by French pathologist Joseph Lieutaud		* '''First Documented Cases:''' 1767 by French pathologist Joseph Lieutaud
	* '''Disease Named:''' 1909 by British pathologist J.G. Adami		* '''Disease Named:''' 1909 by British pathologist J.G. Adami
Line 82:		Line 82:
	The pivotal moment in mesothelioma research occurred in 1960 when J. Christopher Wagner published his landmark study examining 33 cases of diffuse pleural mesothelioma in South Africa's Northwest Cape Province.<ref>[https://pubmed.ncbi.nlm.nih.gov/14445680/ Wagner JC et al. Diffuse pleural mesothelioma and asbestos exposure], PubMed</ref> Wagner's investigation established beyond reasonable doubt that asbestos exposure caused mesothelioma, documenting that all but one patient had probable exposure to crocidolite (blue) asbestos.		The pivotal moment in mesothelioma research occurred in 1960 when J. Christopher Wagner published his landmark study examining 33 cases of diffuse pleural mesothelioma in South Africa's Northwest Cape Province.<ref>[https://pubmed.ncbi.nlm.nih.gov/14445680/ Wagner JC et al. Diffuse pleural mesothelioma and asbestos exposure], PubMed</ref> Wagner's investigation established beyond reasonable doubt that asbestos exposure caused mesothelioma, documenting that all but one patient had probable exposure to crocidolite (blue) asbestos.

	{\| style="width:100%~~; background:#cce5ff~~; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px~~; color:#004085~~;" \| '''ℹ️ Key Discovery:''' Wagner's research identified the typical latency period from asbestos exposure to mesothelioma diagnosis, ranging from 20 to 40 years but extending as long as 71 years in some cases. This long latency explains why mesothelioma cases continued rising for decades after asbestos regulations began.		\| style="padding:15px; " \| '''ℹ️ Key Discovery:''' Wagner's research identified the typical latency period from asbestos exposure to mesothelioma diagnosis, ranging from 20 to 40 years but extending as long as 71 years in some cases. This long latency explains why mesothelioma cases continued rising for decades after asbestos regulations began.
	\|}		\|}

Line 126:		Line 126:
	For more than 15 years, pemetrexed combined with cisplatin represented the standard first-line chemotherapy for unresectable mesothelioma.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pemetrexed-plus-cisplatin-mesothelioma FDA Approves Pemetrexed for Mesothelioma], U.S. Food and Drug Administration</ref> The FDA approved this combination on February 4, 2004, based on a randomized trial demonstrating superior survival (12.1 months vs. 9.3 months) compared to cisplatin alone. This marked the first time the FDA had approved any drug specifically for mesothelioma treatment.<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021462lbl.pdf Alimta (Pemetrexed) FDA Label], FDA</ref>		For more than 15 years, pemetrexed combined with cisplatin represented the standard first-line chemotherapy for unresectable mesothelioma.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pemetrexed-plus-cisplatin-mesothelioma FDA Approves Pemetrexed for Mesothelioma], U.S. Food and Drug Administration</ref> The FDA approved this combination on February 4, 2004, based on a randomized trial demonstrating superior survival (12.1 months vs. 9.3 months) compared to cisplatin alone. This marked the first time the FDA had approved any drug specifically for mesothelioma treatment.<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021462lbl.pdf Alimta (Pemetrexed) FDA Label], FDA</ref>

	{\| style="width:95%; margin:1em auto~~; background:#f8f9fa; color:#333333~~; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "For over 15 years, pemetrexed chemotherapy was the only FDA-approved option for mesothelioma patients. While it extended survival, the field urgently needed more effective treatments. That's why the CheckMate 743 immunotherapy trial represented such a watershed moment for our clients and their families."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "For over 15 years, pemetrexed chemotherapy was the only FDA-approved option for mesothelioma patients. While it extended survival, the field urgently needed more effective treatments. That's why the CheckMate 743 immunotherapy trial represented such a watershed moment for our clients and their families."
Line 137:		Line 137:
	The FDA approval of nivolumab plus ipilimumab on October 2, 2020, represented the most significant advance in mesothelioma treatment since pemetrexed.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref> This dual immune checkpoint inhibitor combination, validated by [[Dr_Paul_Baas\|Dr. Paul Baas's]] [[CheckMate_743_Trial\|CheckMate 743 trial]], became the first new systemic therapy for unresectable mesothelioma in over 15 years.		The FDA approval of nivolumab plus ipilimumab on October 2, 2020, represented the most significant advance in mesothelioma treatment since pemetrexed.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref> This dual immune checkpoint inhibitor combination, validated by [[Dr_Paul_Baas\|Dr. Paul Baas's]] [[CheckMate_743_Trial\|CheckMate 743 trial]], became the first new systemic therapy for unresectable mesothelioma in over 15 years.

	{\| style="width:100%~~; background:#d4edda~~; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px~~; color:#155724~~;" \| '''✅ Immunotherapy Breakthrough:''' The CheckMate 743 trial demonstrated 18.1 months median survival with immunotherapy versus 14.1 months with chemotherapy—a 26% reduction in death risk. For patients with non-epithelioid mesothelioma, survival more than doubled from 8.8 to 18.1 months.		\| style="padding:15px; " \| '''✅ Immunotherapy Breakthrough:''' The CheckMate 743 trial demonstrated 18.1 months median survival with immunotherapy versus 14.1 months with chemotherapy—a 26% reduction in death risk. For patients with non-epithelioid mesothelioma, survival more than doubled from 8.8 to 18.1 months.
	\|}		\|}

Line 211:		Line 211:
	\|}		\|}

	{\| style="width:95%; margin:1em auto~~; background:#f8f9fa; color:#333333~~; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Clinical trials like CheckMate 743 represent hope for mesothelioma patients. Each trial builds on decades of previous research, and when they succeed, they change the lives of thousands of families facing this devastating diagnosis. We encourage eligible patients to discuss clinical trial options with their oncologists."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Clinical trials like CheckMate 743 represent hope for mesothelioma patients. Each trial builds on decades of previous research, and when they succeed, they change the lives of thousands of families facing this devastating diagnosis. We encourage eligible patients to discuss clinical trial options with their oncologists."
Line 255:		Line 255:
	* '''[[Clinical_Trials\|Clinical Trials]]:''' Access to emerging treatments before FDA approval		* '''[[Clinical_Trials\|Clinical Trials]]:''' Access to emerging treatments before FDA approval

	{\| style="width:100%~~; background:#fff3cd~~; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px~~; color:#856404~~;" \| '''⚠️ Treatment Timing Matters:''' Early diagnosis and prompt treatment initiation remain critical factors in mesothelioma outcomes. Patients should seek evaluation at specialized [[Mesothelioma_Treatment_Centers\|mesothelioma treatment centers]] where multidisciplinary teams have experience with this rare disease.		\| style="padding:15px; " \| '''⚠️ Treatment Timing Matters:''' Early diagnosis and prompt treatment initiation remain critical factors in mesothelioma outcomes. Patients should seek evaluation at specialized [[Mesothelioma_Treatment_Centers\|mesothelioma treatment centers]] where multidisciplinary teams have experience with this rare disease.
	\|}		\|}

	{\| style="width:95%; margin:1em auto~~; background:#f8f9fa; color:#333333~~; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "When we first meet with newly diagnosed patients, one of the first things we discuss is treatment options. The research breakthroughs of the past two decades—from pemetrexed to immunotherapy—have given us real hope to share. We've seen firsthand how these advances have extended the lives of our clients and given them precious additional time with their families."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "When we first meet with newly diagnosed patients, one of the first things we discuss is treatment options. The research breakthroughs of the past two decades—from pemetrexed to immunotherapy—have given us real hope to share. We've seen firsthand how these advances have extended the lives of our clients and given them precious additional time with their families."